Overview

Selecting the right patients is the single most important factor in the success of tropomyosin-receptor-kinase inhibition. Entrectinib (Rozlytrek) 200 mg capsules are developed for tumors carrying NTRK gene fusions, regardless of where in the body the tumor originates. This tissue-agnostic, biomarker-led approach means the relevant population is defined by a genomic test rather than by organ site. For B2B buyers, the commercial opportunity tracks the availability of fusion testing in the destination market. We help distributors pair the product with clear guidance on which patients should be referred for molecular screening.

How It Works

Entrectinib inhibits the TRK, ROS1, and ALK tyrosine kinases, blocking proliferative signaling in fusion-driven tumors. Because the target is the genetic alteration itself, a single agent can address lung, salivary, sarcoma, or pediatric central-nervous-system lesions that share the same driver. The agent also penetrates the central nervous system, an attribute that matters for fusion-positive tumors near or within the brain. From a clinical-procurement view, demand is concentrated wherever comprehensive genomic profiling is routinely performed.

Indications

The capsules are indicated for NTRK fusion-positive solid tumors in adults and certain pediatric patients, and for ROS1-positive non-small-cell lung cancer. Eligibility depends on a confirmed molecular result, not on tumor histology alone. Buyers should check both the adult and pediatric indications written into each country's approval. We supply the 200 mg strength to match published combination-independent dosing schedules.

Dosage & Administration

Entrectinib is generally given as a once-daily oral capsule, with the dose calculated from body surface area per the local label. Capsules should be swallowed whole and stored in the original container with the desiccant. Because eligibility rests on a genomic report, procurement should be linked to testing volume rather than to general oncology census. We advise forecasting demand from the local molecular-diagnostics throughput.

Storage & Sourcing

Keep the capsules at 2-8°C and shield them from excess moisture during handling. Our export process uses temperature-controlled packaging with documented transit logging. Lead times and minimum order quantities are set per destination and registration status. We support distributors with batch-release paperwork suited to pharmacy and customs acceptance.

FAQ

Q: Which patients should be tested before Entrectinib is considered? Any advanced solid tumor lacking a standard driver should be screened for NTRK fusions and ROS1 rearrangements through comprehensive genomic profiling.

Q: Why is this described as a tissue-agnostic therapy? Eligibility follows the presence of a target fusion, so the same agent applies across lung, sarcoma, salivary, and CNS lesions sharing that driver.

Q: Is central-nervous-system activity relevant for buyers? Yes. The agent reaches the CNS, which is important for fusion-positive tumors located near or within the brain.

Q: How should distributors forecast demand? Base forecasts on local molecular-testing volume rather than on total oncology patient counts.